A Phase I Trial of Interleukin-2 (Aldesleukin) and Pembrolizumab Combination Therapy for Patients With Advanced Renal Cell Carcinoma
Phase of Trial: Phase I
Latest Information Update: 22 Nov 2018
At a glance
- Drugs Aldesleukin (Primary) ; Aldesleukin (Primary) ; Pembrolizumab (Primary)
- Indications Carcinoma; Renal cell carcinoma
- Focus Adverse reactions
- 19 Sep 2018 Planned End Date changed from 17 Mar 2022 to 17 Mar 2021.
- 19 Sep 2018 Planned primary completion date changed from 17 Mar 2022 to 17 Mar 2021.
- 19 Sep 2018 Status changed from not yet recruiting to recruiting.